These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14698157)

  • 1. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding.
    Fraley ME; Arrington KL; Buser CA; Ciecko PA; Coll KE; Fernandes C; Hartman GD; Hoffman WF; Lynch JJ; McFall RC; Rickert K; Singh R; Smith S; Thomas KA; Wong BK
    Bioorg Med Chem Lett; 2004 Jan; 14(2):351-5. PubMed ID: 14698157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.
    Bell IM; Gallicchio SN; Abrams M; Beese LS; Beshore DC; Bhimnathwala H; Bogusky MJ; Buser CA; Culberson JC; Davide J; Ellis-Hutchings M; Fernandes C; Gibbs JB; Graham SL; Hamilton KA; Hartman GD; Heimbrook DC; Homnick CF; Huber HE; Huff JR; Kassahun K; Koblan KS; Kohl NE; Lobell RB; Lynch JJ; Robinson R; Rodrigues AD; Taylor JS; Walsh ES; Williams TM; Zartman CB
    J Med Chem; 2002 Jun; 45(12):2388-409. PubMed ID: 12036349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
    Bilodeau MT; Balitza AE; Koester TJ; Manley PJ; Rodman LD; Buser-Doepner C; Coll KE; Fernandes C; Gibbs JB; Heimbrook DC; Huckle WR; Kohl N; Lynch JJ; Mao X; McFall RC; McLoughlin D; Miller-Stein CM; Rickert KW; Sepp-Lorenzino L; Shipman JM; Subramanian R; Thomas KA; Wong BK; Yu S; Hartman GD
    J Med Chem; 2004 Dec; 47(25):6363-72. PubMed ID: 15566305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase A-mediated phosphorylation of HERG potassium channels in a human cell line.
    Wei Z; Thomas D; Karle CA; Kathöfer S; Schenkel J; Kreye VA; Ficker E; Wible BA; Kiehn J
    Chin Med J (Engl); 2002 May; 115(5):668-76. PubMed ID: 12133532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
    Busch AE; Eigenberger B; Jurkiewicz NK; Salata JJ; Pica A; Suessbrich H; Lang F
    Br J Pharmacol; 1998 Jan; 123(1):23-30. PubMed ID: 9484850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
    Ficker E; Jarolimek W; Brown AM
    Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A minK-HERG complex regulates the cardiac potassium current I(Kr).
    McDonald TV; Yu Z; Ming Z; Palma E; Meyers MB; Wang KW; Goldstein SA; Fishman GI
    Nature; 1997 Jul; 388(6639):289-92. PubMed ID: 9230439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
    Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
    J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionally-distinct proton-binding in HERG suggests the presence of two binding sites.
    Bett GC; Rasmusson RL
    Cell Biochem Biophys; 2003; 39(3):183-93. PubMed ID: 14716075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X).
    Thomas D; Hammerling BC; Wimmer AB; Wu K; Ficker E; Kuryshev YA; Scherer D; Kiehn J; Katus HA; Schoels W; Karle CA
    Cardiovasc Res; 2004 Dec; 64(3):467-76. PubMed ID: 15537500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity.
    Zhang Y; Wang H; Wang J; Han H; Nattel S; Wang Z
    FEBS Lett; 2003 Jan; 534(1-3):125-32. PubMed ID: 12527373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
    Zhang S; Zhou Z; Gong Q; Makielski JC; January CT
    Circ Res; 1999 May; 84(9):989-98. PubMed ID: 10325236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I(Kr): the hERG channel.
    Tseng GN
    J Mol Cell Cardiol; 2001 May; 33(5):835-49. PubMed ID: 11343409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
    Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
    Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open channel block of HERG K(+) channels by vesnarinone.
    Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
    Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
    Spector PS; Curran ME; Keating MT; Sanguinetti MC
    Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
    Thomas D; Kathofer S; Zhang W; Wu K; Wimmer AB; Zitron E; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2003 Nov; 140(5):996-1002. PubMed ID: 14517175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel.
    Tinel N; Diochot S; Borsotto M; Lazdunski M; Barhanin J
    EMBO J; 2000 Dec; 19(23):6326-30. PubMed ID: 11101505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
    Finlayson K; Pennington AJ; Kelly JS
    Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.